D-1178-2023 Class III Terminated

Recalled by Tolmar, Inc. — Fort Collins, CO

FDA drug recall D-1178-2023 was initiated by Tolmar, Inc. on Sep 12, 2023 and is designated Class III. Reason for recall: Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product. The recall status is terminated (terminated Oct 3, 2024). Affected quantity: 2990 cartons.

Recall details

Product Type
Drugs
Report Date
Oct 4, 2023
Initiation Date
Sep 12, 2023
Termination Date
Oct 3, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2990 cartons

Product description

Eligard (leuprolide acetate) for injectable suspension, 7.5 mg every month, Sterile, Rx Only, Must be reconstituted before use, NDC 62935-753-75, Manufactured by: Tolmar Inc., Fort Collins, CO 80526, For Tolmar Therapeutics Inc., Fort Collins, CO 80526.

Reason for recall

Superpotent Drug - Higher than expected levels of leuprolide acetate in the constituted product.

Distribution pattern

Nationwide in the US.

Code information

Lot: 13635A1, Exp. 07/31/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1178-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1178-2023. Report a data issue: hello@regdatalab.com.